Search Results
Your search for ,wAS matches 27441 pages
Showing 10701 - 10750Nivolumab in Previously Treated Esophageal Squamous Cell Carcinoma
On June 10, 2020, nivolumab was approved for treatment of patients with unresectable, advanced, recurrent, or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.1,2 Supporting Efficacy Data Approval was based on findings from the open-label,...
Bishal Gyawali, MD, PhD, Receives Young Health Researcher Award From Nepali Government
At the Sixth National Summit of Health and Population Scientists, held in Kathmandu, Nepal, Bishal Gyawali, MD, PhD, was awarded the Mrgendra Samjhana Medical Trust Young Researcher Award. The annual conference is organized by the Nepal Health Research Council, an autonomous body of the Government...
Phase III PADA-1 Trial Examines the Impact of ESR1 Mutations in Metastatic Breast Cancer
ESR1 mutations are known to confer resistance to endocrine therapy in the metastatic breast cancer setting. These mutations herald a poor prognosis, so their clearance early in the treatment course may greatly reduce the risk of recurrence, according to the early results of the prospective phase...
Two Cohort Studies Identify Risk Factors for Mortality in Patients With Cancer and COVID-19
Two studies recently reported in The Lancet have identified risk factors for mortality among patients with cancer and COVID-19.1,2 As reported by Lennard Y.W. Lee, DPhil, of the Institute of Cancer and Genomic Sciences, University of Birmingham, and colleagues,1 a UK prospective cohort study...
Expert Point of View: Komal Jhaveri, MD
“Surprisingly, the phase II PARSIFAL trial did not show a statistical superiority in progression-free survival for fulvestrant plus palbociclib over letrozole plus palbociclib in the first-line treatment of patients with endocrine-sensitive, metastatic breast cancer. The noninferiority hypothesis...
When Paired With Palbociclib, Fulvestrant and Letrozole Yield Comparable Results in PARSIFAL Trial
When paired with palbociclib in the first-line treatment of metastatic breast cancer, fulvestrant and letrozole performed comparably, with no statistical superiority in progression-free or overall survival shown for either endocrine agent, in the phase II PARSIFAL study presented during the ASCO20...
Pembrolizumab for Adult and Pediatric Patients With Tumor Mutational Burden–High Solid Tumors
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On June 16, 2020, pembrolizumab was granted accelerated...
In Case You Missed It: Quick Takes on Novel Therapies for Solid and Hematologic Malignancies
Because of the COVID-19 pandemic, oncology providers from around the world had to forgo their annual trip to McCormick Place—but the show did go on. We all realized important research can still be presented, clinicians and fellow researchers will still listen, and ASCO presentations will still...
Double PIK3CA Mutations and Response Benefit in Breast Cancer
Patients who have breast cancers with double PIK3CA mutations seem to have a more robust response to PI3Kα inhibitors than those with a single PIK3CA mutation, based on an analysis of the phase III SANDPIPER trial, which tested taselisib plus fulvestrant, according to a presentation during the 2020 ...
Expert Point of View: Ahmad Tarhini, MD, PhD, and Larisa J. Geskin, MD
Ahmad Tarhini, MD, PhD, Director of Cutaneous and Translational Research at Moffitt Cancer Center, Tampa, was optimistic about neoadjuvant use of nivolumab/ipilimumab and looks forward to further randomized studies. “Taken together, the results of the OpACIN and OpACIN-neo trials support the value ...
Small Study Evaluates Neoadjuvant vs Adjuvant Nivolumab Plus Ipilimumab in Stage III Melanoma
The neoadjuvant combination of nivolumab and ipilimumab yielded a continued benefit in relapse-free survival vs adjuvant use of the same combination therapy in 20 patients with stage III macroscopic melanoma. This finding is based on 3-year follow-up results of the phase Ib OpACIN trial, presented...
AACR Holds COVID-19 and Cancer Virtual Meeting
The American Association for Cancer Research (AACR) hosted a virtual meeting on COVID-19 and cancer earlier this month (July 20–22, 2020). The virtual event, “COVID-19 and Cancer,” featured presentations from leaders in the fight against the pandemic, including three keynote lectures. In an opening ...
Expert Point of View: Alexander Drilon, MD
Discussant of the TATTON study presentation, Alexander Drilon, MD, Chief of Early Drug Development at Memorial Sloan Kettering Cancer Center, New York, finds the idea of combination therapy with a MET inhibitor and an EGFR tyrosine kinase inhibitor attractive for the treatment of EGFR...
ctDNA Clearance Predicts Progression-Free Survival With Osimertinib/Savolitinib in EGFR-Mutant, MET-Amplified NSCLC
Circulating tumor DNA (ctDNA) clearance of EGFR mutation—that is, detectable mutation at baseline that became undetectable or dropped below a predetermined threshold—appears to be predictive of extended progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung...
ASTRO to Host Virtual Annual Meeting, October 25–28, 2020
The American Society for Radiation Oncology (ASTRO) has announced it will hold its 62nd Annual Meeting October 25–28, 2020, via an interactive virtual platform. The meeting, “Global Oncology: Radiation Therapy in a Changing World,” will feature reports from the latest clinical trials; panels on...
Expert Point of View: John D. Minna, MD
John D. Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research at The University of Texas Southwestern Medical Center, Dallas, was enthusiastic about this approach. “When I first heard about it, I was so...
Can Radiomics Predict Survival in Patients With NSCLC Receiving Immunotherapy?
Immunotherapy with immune checkpoint inhibitors has made great strides in the treatment of many cancers, but only between 25% and 50% of patients respond with clinical benefit, and these agents come with adverse events and high price tags. Thus, preselection of patients who are likely to respond to ...
Monumental Progress in the Treatment of Diffuse Large B-Cell Lymphoma
Some monuments are difficult to topple. At least that was the case dating back to 1976, when investigators from the Southwest Oncology Group demonstrated the importance of doxorubicin in the treatment of patients with a group of lymphoid malignancies then referred to as diffuse aggressive...
The Need for Solid Data During a Global Pandemic
The rapid outbreak of COVID-19 disease on a global scale found the community of clinicians and scientists largely unprepared to face the devastating effects of the pandemic. The stress on health-care systems revealed their weaknesses and brought about associated financial crises. Defining the...
Nivolumab/Ipilimumab Shows Benefit in Patients With Non–Small Cell Lung Cancer and Brain Metastases
The combination of nivolumab plus ipilimumab was at least as effective as chemotherapy in front-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and brain metastases at baseline, according to the results of a post hoc analysis from part 1 of the phase III CheckMate 227...
T-DM1 in Patients With HER2-Positive Breast Cancer and Brain Metastases: KAMILLA Trial
An exploratory subgroup analysis of the KAMILLA trial represents the largest reported cohort of patients with HER2-positive breast cancer and brain metastases treated with the anti-HER2 antibody-drug conjugate ado-trastuzumab emtansine, or T-DM1, in a prospective setting. Researchers observed...
Updated CCC19 Data Offer Insights on Treatment for Patients With Cancer and COVID-19 Infection
Newly released data on treatment outcomes of patients with cancer infected with COVID-19 revealed a racial disparity in access to remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite...
First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer
In a single-institution retrospective study reported in JAMA Surgery, Perri et al found that first-line FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) was associated with a higher response rate and subsequent pancreatectomy vs gemcitabine plus nab-paclitaxel in patients with...
Outcomes With Axicabtagene Ciloleucel in the Nontrial Setting in Patients With B-Cell Non-Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Caron A. Jacobson, MD, and colleagues found that commercial use of the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in patients with relapsed or refractory B-cell non-Hodgkin lymphoma was associated with an overall...
Effect of Breast Cancer Pathway Implementation on Rate of Referrals for Genetic Counseling and Testing
In a study reported in JCO Oncology Practice, Stephanie L. Graff, MD, and colleagues found that patients with breast cancer seen by a physician with training in using an established pathway for genetic counseling and testing referral were more frequently referred for such services vs patients seen...
EAU Virtual: EUPROMS Study Investigates Effect of Prostate Cancer Treatment on Quality of Life
Findings from the first international prostate cancer quality-of-life study showed that significant numbers of men treated for the disease are struggling with continence and sexual problems after treatment. Results suggest that any treatment apart from active surveillance may negatively affect...
Study Finds Higher Risk for COVID-19 Infection Among Minorities and Patients With Cancer
According to the latest data from the Centers for Disease Control and Prevention, Native American or Alaska Native and non-Hispanic Black people have the highest rates of hospitalization or death from COVID-19, followed by Hispanics and Latinos. A large population-based study using a smartphone app ...
Addition of Antithymocyte Globulin to Graft-vs-Host Disease Prophylaxis in Matched Sibling Donor Stem Cell Transplant
In a Chinese trial reported in the Journal of Clinical Oncology, Chang et al found that the addition of antithymocyte globulin to standard graft-vs-host disease prophylaxis reduced the risk of acute graft-vs-host disease in patients undergoing human leukocyte antigen (HLA)-matched sibling donor...
Avapritinib in Advanced PDGFRA D842V–Mutant Gastrointestinal Stromal Tumors
As reported in The Lancet Oncology by Heinrich et al, the phase I NAVIGATOR trial showed that the PDGFRA and KIT kinase inhibitor avapritinib produced a response in patients with PDGFRA D842V–mutant gastrointestinal stromal tumors (GIST). The study supported the January 2020 approval of...
In Keynote Lecture, Anthony Fauci, MD, Explores What We Know About COVID-19 and What’s Being Done to Combat It
Kicking off the American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer earlier this week, Anthony Fauci, MD, gave the keynote lecture, “Coronavirus Infections: More Than Just the Common Cold.” As Dr. Fauci told listeners, “[COVID-19]—and other infectious...
Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted
People of any age with serious underlying health conditions are at greater risk for contracting the coronavirus, and cancer survivors are particularly vulnerable to becoming infected with COVID-19, since many cancer therapies can lead to immunosuppression. To reduce exposure to the virus, the...
Adjuvant Chemotherapy vs Active Surveillance: Survival After Resection of Isolated Synchronous Colorectal Peritoneal Metastases
In a Dutch population-based observational cohort study reported in JAMA Oncology, Rovers et al found that adjuvant systemic chemotherapy was associated with improved overall survival vs active surveillance after upfront resection of isolated synchronous colorectal peritoneal metastases. Study...
Margetuximab/Pembrolizumab for Previously Treated Patients With HER2-Positive Advanced Gastroesophageal Adenocarcinoma
In a phase Ib/II trial reported in The Lancet Oncology, Daniel V.T. Catenacci, MD, and colleagues found that the combination of margetuximab and the anti–PD-1 therapy pembrolizumab showed evidence of activity in patients with previously treated HER2-positive gastroesophageal adenocarcinoma. As...
Long-Term Normal Tissue Effects With Five-Fraction Whole-Breast Radiotherapy for Early Breast Cancer
As reported in the Journal of Clinical Oncology by Brunt et al, 10-year follow-up in the FAST trial of women with early breast cancer showed greater risk for photographic- and physician-assessed normal tissue effects with an adjuvant radiotherapy regimen of 30 Gy in 5 once-weekly fractions—but not...
Longitudinal Analysis of Health-Related Quality of Life in Patients With Hodgkin Lymphoma
A longitudinal analysis of health-related quality of life in patients from German Hodgkin Study Group trials, reported in the Journal of Clinical Oncology by Kreissl et al, showed a “high and persistent” amount of health-related quality-of-life deficits in survivors of Hodgkin lymphoma. The...
Pembrolizumab for Advanced Melanoma: Impact of BRAF-Mutation Status and Prior Therapeutic Regimens
In a pooled analysis reported in JAMA Oncology, Igor Puzanov, MD, MSCI, and colleagues identified objective response rates and progression-free and overall survival rates with pembrolizumab treatment among patients with advanced melanoma according to BRAF V600E/K–mutation status and prior BRAF/MEK...
Phase Ib Trial of Atezolizumab With or Without Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
The combination of atezolizumab and bevacizumab was recently approved by the U.S. Food and Drug Administration for the treatment of unresectable or metastatic hepatocellular carcinoma on the basis of findings from the phase III IMbrave150 trial, which showed superior overall and progression-free...
SNMMI 2020: First Results of Total-Body Dynamic PET Scan in Patients With Cancer
Results from the first study using uEXPLORER to conduct total-body dynamic positron-emission tomography (PET) scans in patients with cancer suggested that it can be used to generate high-quality images of metastatic cancer. The research was presented at the Society of Nuclear Medicine and Molecular ...
SNMMI 2020: Role of PSMA PET/CT in the Management of Recurrent Prostate Cancer
New research outlines the role of prostate-specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) in the detection and management of recurrent disease in prostate cancer patients. In initial results from a multicenter trial assessing the impact of F-18 DCFPyL...
SNMMI 2020: Novel PET Radiotracer for Glioblastoma
A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting and published by Zhang et al in the Journal of Nuclear Medicine has demonstrated the safety and favorable pharmacokinetic and dosimetry profile of Cu-64 EBRGD, a new, relatively...
LACC Trial: Quality of Life With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer
As reported in The Lancet Oncology by Frumovitz et al, there were no significant differences in quality of life, a secondary endpoint, for women undergoing open vs minimally invasive radical hysterectomy for cervical cancer in the phase III LACC trial. There were, however, differences in...
Effect of Complete vs Incomplete Macroscopic Excision on Survival in Stage IV High-Risk Neuroblastoma
In an analysis from the International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) High-Risk Neuroblastoma 1 (HR-NBL1/SIOPEN) trial reported in the Journal of Clinical Oncology, Holmes et al found that surgeon-assessed complete macroscopic excision was associated with improved...
Expert Point of View: Alice Mims, MD
Alice Mims, MD, Associate Professor of Hematology at The Ohio State University Comprehensive Cancer Center–The James, shared her insights on the VIALE-A study. “The results of the VIALE-A study have been highly anticipated and are exciting, given the improvement seen in both overall survival and...
VIALE-A Trial Supports Survival Benefit of Venetoclax Plus Azacitidine in Elderly Patients With AML
In the phase III VIALE-A trial, venetoclax added to azacitidine led to a significant and clinically meaningful improvement in response rates and overall survival, as compared with azacitidine alone, in treatment-naive predominantly elderly patients with acute myeloid leukemia (AML) ineligible for...
Study Links Mental Health Treatment to Possible Improved Cancer Survival
For people with cancer who have a mental health disorder, getting mental health treatment may help them live longer, a new study published by Berchuck et al in JAMA Oncology suggests. In the retrospective study, of more than 50,000 veterans treated for lung cancer within the Veterans Affairs (VA)...
Study Identifies Factors That May Predict Toxicities in Patients Treated With CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has proved to be a valuable treatment option for patients with lymphoma in whom other therapies have failed. In clinical trials, the cellular immunotherapy was shown to provide durable remissions for nearly 40% of patients with large B-cell lymphoma....
Quality of Life With Timing of Platinum-Based Regimens in Newly Diagnosed Patients With Ovarian Cancer
In a study reported in The Lancet Oncology, Blagden et al found lower mean global quality-of-life scores on longitudinal analysis among women with newly diagnosed ovarian cancer who received weekly vs every-3-week paclitaxel in platinum-based regimens in the ICON8 trial. The ICON8 trial showed no...
Effectiveness of Routine Blood Testing in Detection of Disease During Active Surveillance for Indolent Non-Hodgkin Lymphoma
In an Australian study reported in JCO Oncology Practice, Piercey et al found that routine blood tests have little utility in detecting relapse or progression of disease during active surveillance of patients with indolent non-Hodgkin lymphoma. As stated by the investigators, “Patients with...
Outcomes According to BMI in Women Receiving Adjuvant Docetaxel-Based Chemotherapy for Early Breast Cancer
A retrospective analysis from the BIG 2-98 trial reported in the Journal of Clinical Oncology by Desmedt et al showed poorer disease-free and overall survival with increasing baseline body mass index (BMI) in women receiving adjuvant docetaxel-based chemotherapy but not among those receiving...
Two Studies Focus on Emerging Treatment Options for Patients With Neuroendocrine Tumors
Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, and published in Oncotarget and Cancer, respectively, highlight possible new treatment options for patients with neuroendocrine tumors. SurVaxM The first report,...
